Oakmark Funds, advised by Harris Associates, released its “Oakmark Global Fund” second quarter 2025 investor letter. The fund ...

Becton Dickinson & Co. closed 28.21% short of its 52-week high of $251.99, which the company reached on February 3rd.

Becton, Dickinson and Company is an attractive firm that just made a good deal. Click here to find out why BDX stock is a Buy ...

Heartland Advisors, an investment management company, released its “Heartland Mid Cap Value Fund” second quarter 2025 ...

Becton Dickinson will spin off its biosciences and diagnostic business and merge it with Waters, and plans to use at least $2 ...

Becton, Dickinson's divestment enhances focus, reduces leverage, funds buybacks, and unlocks value. Read more about the M&A ...

Key Takeaways Waters said it reached a deal to buy the Biosciences & Diagnostic Solutions business of Becton Dickinson for ...

BDX collaborates with Waters in a $17.5B deal to form a diagnostics powerhouse targeting $9B in revenues by 2030.

Shares of Becton Dickinson and Company BDX are currently in its 17th phase of the 18-phase Adhishthana Cycle, and signs point toward continued underperformance and consolidation, likely lasting ...

BECTON, DICKINSON posted quarterly earnings results on Thursday, May 1st.The company reported earnings of $3.35 per share, beating estimates of $3.31 by $0.04. The company also reported revenue of ...